Evercore ISI has upgraded CRISPR Therapeutics (CRSP, Financial) to Outperform, citing multiple upcoming catalysts that could drive the stock higher.
The firm is now factoring in CTX320 and CTX310 in vivo programs into its price target, assigning a 10% probability of success for CTX320 and 5% for CTX310. Data for CTX320 is expected in Q2, while CTX310 results are also anticipated later this year.
Additional key catalysts include:
Evercore also highlighted anticipated strong growth in cell collections for Casgevy, CRISPR's gene-editing therapy co-marketed with Vertex Pharmaceuticals (VRTX, Financial).
Reflecting these potential tailwinds, Evercore raised its price target on CRSP to $99 from $60.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。